



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

6 October 2023
EMA/CVMP/432172/2023
Committee for Veterinary Medicinal Products

Summary of opinion¹ (initial authorisation)

Senvelgo

International non-proprietary name (INN): velagliflozin

On 5 October 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion², recommending the granting of a marketing authorisation for the veterinary medicinal product Senvelgo, intended for cats. The applicant for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.

Senvelgo is a medicinal product containing velagliflozin L-proline monohydrate as active substance (ATCvet code QA10BK90), a sodium-dependent glucose co-transporter 2 (SGLT-2) inhibitor. Inhibition of SGLT-2 decreases renal glucose reabsorption, which reduces blood glucose levels and thus allows for the control of hyperglycaemia.

The main benefit of Senvelgo is the reduction of hyperglycaemia in cats with non-insulin-dependent diabetes mellitus.

The most common side effects are diarrhoea or loose stool, polydipsia or polyuria, weight loss, dehydration and vomiting.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC), which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Senvelgo and therefore recommends the granting of the marketing authorisation.

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

